Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Hi, everyone. Thank you for joining us on -- here on day 3 of the 42nd Annual Goldman Sachs Global Healthcare Conference. I'm Paul Choi, and I cover the smid cap biotechnology sector here at the firm. Our next session will be with Magenta, and joining us from the company is CEO, Jason Gardner. (Operator Instructions)
And with that, I'll turn it over to Jason for some opening comments and an overview of Magenta. Jason?
Great. Well, first of all, thank you, Paul, and the Goldman team for the opportunity to participate in the Goldman conference this year. I'd also like to thank the Magentini, all of our partners, our investors and the patients and their families for their commitment to our vision. And we've made terrific progress this year.
So let me just begin by framing Magenta as a company. We are the only stem cell transplant-focused platform biotech. We have 2 programs that are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
